Lumosity DTx
Phase 3- Indications
- Adult ADHD
Company intelligence / Profile preview
Lumos Labs has developed widely used digital brain training programs reaching over 100 million users globally. Their medical division, Lumosity DTx, is developing digital therapeutics and assessment tools for neurological and cognitive conditions. While their software has been studied in at least 19 clinical populations—including ADHD, mild cognitive impairment, stroke, and traumatic brain injury—no product is yet FDA-cleared to diagnose or treat disease. Over 90 peer-reviewed studies support the evidence base behind their approach.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lumos Labs Medical.